Pacira Pharmaceuticals (PCRX) Given “Buy” Rating at HC Wainwright

Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Monday, MarketBeat Ratings reports. They currently have a $48.00 price objective on the stock, up from their prior price objective of $45.00. HC Wainwright’s target price indicates a potential upside of 43.50% from the company’s current price.

Other equities research analysts have also issued research reports about the company. ValuEngine upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Piper Jaffray set a $44.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. BMO Capital Markets reduced their price objective on Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Thursday, March 1st. Seaport Global Securities set a $48.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, April 8th. Finally, BidaskClub lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $44.35.

Shares of Pacira Pharmaceuticals stock traded down $1.10 during trading on Monday, reaching $33.45. 1,628,686 shares of the company’s stock were exchanged, compared to its average volume of 1,212,933. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.96 and a quick ratio of 6.22. Pacira Pharmaceuticals has a 1-year low of $26.95 and a 1-year high of $52.47.



Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The company had revenue of $79.08 million during the quarter, compared to analysts’ expectations of $79.06 million. During the same quarter in the previous year, the firm earned $0.09 EPS. Pacira Pharmaceuticals’s revenue was up 8.5% on a year-over-year basis. sell-side analysts anticipate that Pacira Pharmaceuticals will post -0.51 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC bought a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $845,000. Redmile Group LLC bought a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $237,000. Element Capital Management LLC bought a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $6,144,000. Macquarie Group Ltd. grew its position in shares of Pacira Pharmaceuticals by 9.7% in the 4th quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after buying an additional 111,869 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at about $501,000.

ILLEGAL ACTIVITY WARNING: “Pacira Pharmaceuticals (PCRX) Given “Buy” Rating at HC Wainwright” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://dakotafinancialnews.com/2018/04/11/pacira-pharmaceuticals-pcrx-stock-rating-reaffirmed-by-hc-wainwright.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply